Trial site
MSK Commack.
Commack, New York, United StatesNot linked to an institution yet
- 17running trials
- 4closed trials
- 0trials confirmed by the site in the last 60 days
- –languages not stated
The site has not confirmed any trial yet.
Running trials
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287· Phase 2· Source
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· Phase 1/2· Source
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· Phase 1/2· Source
Recruiting
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT07206225· Phase 1· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983· Phase 2· Source
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· Phase 2· Source
Active, not recruiting
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118· Phase 1· Source
Active, not recruiting
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837· Phase 1/2· Source
Active, not recruiting
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· Phase 3· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130· Phase 1· Source
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· Phase 3· Source
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· Phase 3· Source
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· Phase 2· Source
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· Phase 3· Source
Active, not recruiting
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05059522· Phase 3· Source
Active, not recruiting
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209· Phase 2· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Researchers
No researcher is linked here yet.
Report an error